Biotech Values

[walldiver]

Clinical-trial / regulatory calendar:

[Please see updating procedure at the end of this post.]


Edits: CRME today released ACT 3 RSD 1235 results. COM will report ACT 2 RSD 1235 results in Q4/05 or Q1/06;

Edit #2: DNDN 10/31/05 full survival data (and possibly less important ttp data as well) from Provenge 9902A trial to be presented at ECCO; and removal of 1H 2006 ttp endpoint unblinding from 9902B trial, as the SPA has been amended



ABGX- international Panitumumab phase-3 results in refractory mCRC: late 3Q05 or early 4Q05.

AGEN - Ph III in melanoma 2H05, Ph III in RCC 1H06.

AGIX - 1H 06 - Ph iii of 1067 on MACE should hit 900+ events for the end of the trial.

ALKS – 12/30/05 PDUFA date for Vivitrex NDA.

AORMF -pivotal AMD3100 results 2nd half 06.

AVN – FDA acceptance for filing of NDA for PBA: delayed (was 10/10/05).

AXCA -pivotal Itax results 1st half 06.

BMY – 12/31/05 revised action date for Orencia (CTLA-4).

BOMSF -reporting pivotal MBP8298 results 2 years roughly

CEPH – Attenace (Provigil) PDUFA date in ADHD: 9/05; Nuvigil PDUFA date in EDS: 1/06; Oravescent Fentanyl PDUFA date: 7/6/06.

COR - Oct 2005: Interim analysis - IIa Alzheimer's CX-717 Ampakine trial.
COR - Approx Year end 2005: Results of IIa ADHD CX-717 Ampakine trial.
COR - Early 2006: Results of IIa Simulated Night Shift Work (Sleep Disorder) CX-717 Ampakine trial (funded by DARPA).

CORT - 1H 06 - Results of Ph iii of RU-486 on Psychotic MD

CRME - Phase III RSD1235 ACT 2 CABG data in Q4/05 or Q1/06

CNVX - Last interim look at melanoma vaccine in Q3/Q4 05

CYAHF -20 patient IDE results 4th qtr, then begin the pivotal phase 1st half 06 as well as commercial launch in Europe later this year.

CYPB – Phase-3 Milnacipran in fibromyalgia, second phase-3 study (either 3-mo or 6-mo of follow-up) 3Q06 (maybe —Dew).

DNA - Rituxan ph III results in RA in Q3 05
DNA - Lucentis phase-3 ANCHOR in 4Q05.

DNDN - 10/31/05 full survival data (and possibly less important ttp data as well) from Provenge 9902A trial to be presented at ECCO
DNDN - 1H 06 - Results for Ph iii of Provenge efficacy on PSADT in ADPC

FRX - Milnacipran in fibromyalgia: see CYPB entry

GENR – Phase-2 AMD data from “208” trial at AAO: 10/05; start of second phase-3 AMD trial: 2H05.

GPCB – Satraplatin SPARC trial: interim efficacy 1Q06, final efficacy 2Q06. (Endpoint is a complex TTP metric.)

GTCB – EMEA opinion on ATryn: Feb. 2006

IDBE -begin pivotal Fluinsure trials this winter.

IMCL – Erbitux H&N PDUFA date: late Feb 06 (sBLA submitted 8/30/05).

INSM - pdufa date for somatokine 10/03/05

ISTKF -report interim Phase III ISA247 psoriasis results August and unblinded results in October.

LBPFF -report Tramadol Phase III U.S. results 2nd half as well as European launch 4th qtr.

LRP -report pivotal viruzulin results later this year (2005).

MYOG - Top-line data from Ambrisentan phase-3 trials in PAH: ARIES-2 in 4Q05, ARIES-1 in 2Q06.

NABI - ph iii results for vaccine against staph in Q3/Q4 05

NKTR – Exubera endorsed by advisory panel 9/8/05 by 7-2 vote, awaiting FDA action.

NVS – LAF237 pivotal data in diabetes: early 2006.

ORPH (to become JAZZ?)--2H 05-data from the clinical trial designed to evaluate Xyrem in the treatment of fibromyalgia syndrome

PDLI - Q2 06 volociximab ph II for solid tumors

PTIE - All are 2H05
Oxytrex(TM) Osteoarthritic Pain - Phase III Report top-line results
PTI-901 Irritable Bowel Syndrome - P.III Report top-line results in women

PTN- Q2 2006 ph.IIb results for PTN-141 in male erectile dysfunction

RNAI – Sirna-007 final phase-1 AMD data at AAO: 10/05.

SPPI – See GPCB.

TELK - Telcyta 3rd line NSCLC and 3rd line Ovarian results 1H06

TH.TO -report ThGrf Phase III Hiv-associated lipodystrophy results late 06.

VSGN - Celacade phase-3 in chronic HF (ACCLAIM) fiscal 1Q06 (Dec 05-Feb 06).

YMI - early 2006?--672 patients enrolled, 28 to go.YM anticipated that the trial might be completed as early as mid-2006, but seems to be potentially ahead of schedule.
YMI - report pivotal Tesmilifine breast cancer results possibly 2nd qtr 06.
YMI – AeroLEF phase-2b data report: 2Q06.


--
Procedure For Updating Clinical-Trials List

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old list. You can find a pointer to this list in the iBox at the top of the main message-board screen.

2. Make your additions or modifications, inserting any new items in alphabetical order.

3. Post the updated text in a new message in reply to the message with the old list.


Let’s talk biotech!
When assessing the smarts of the average investor, bear in mind that one in four people believes the drug industry has a secret cure for cancer!